Virology
Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity

https://doi.org/10.1016/j.diagmicrobio.2017.07.006Get rights and content

Highlights

  • •

    Serologic responses of 42 MERS-CoV-infected patients were evaluated.

  • •

    Patients were divided into 4 disease severity groups.

  • •

    The seroconversion rate gradually increased with increasing disease severity.

  • •

    Seventy-five percent of deceased patients did not show seroconversion by the third week.

Abstract

We evaluated serologic response of 42 Middle East respiratory syndrome coronavirus (MERS-CoV)-infected patients according to 4 severity groups: asymptomatic infection (Group 0), symptomatic infection without pneumonia (Group 1), pneumonia without respiratory failure (Group 2), and pneumonia progressing to respiratory failure (Group 3). None of the Group 0 patients showed seroconversion, while the seroconversion rate gradually increased with increasing disease severity (0.0%, 60.0%, 93.8%, and 100% in Group 0, 1, 2, 3, respectively; P = 0.001). Group 3 patients showed delayed increment of antibody titers during the fourth week, while Group 2 patients showed robust increment of antibody titer during the third week. Among patients having pneumonia, 75% of deceased patients did not show seroconversion by the third week, while 100% of the survived patients were seroconverted (P = 0.003).

Keywords

Middle East respiratory syndrome coronavirus
Prognosis
Antibody
Serologic response

Cited by (0)

1

These authors contributed equally to this article as first authors.

2

Present address: Division of Infectious Diseases, Department of Internal Medicine, Armed Forces Capital Hospital, Seongnam, Korea.

3

These corresponding authors contributed equally to this article.

View Abstract
© 2017 Elsevier Inc. All rights reserved.